
Company Legal Name
Latest Valuation
Founded Year
Headquarters
Colossal Biosciences Inc. is a biotechnology company pioneering advanced gene editing technologies to revive extinct species and conserve endangered wildlife. Based in Dallas, the company combines cutting-edge CRISPR gene editing, computational biology, and reproductive technologies to restore lost biodiversity. Colossal's groundbreaking approach positions it at the forefront of the emerging de-extinction field, targeting iconic species including the woolly mammoth, Tasmanian tiger, and dodo bird. The company's innovative platform addresses critical environmental challenges while creating potential commercial applications in conservation biology, synthetic biology, and pharmaceutical development. Colossal continues expanding its scientific capabilities and species portfolio to advance global conservation efforts.

Availability of information and platform features may vary by region and applicable requirements.
Eligibility and access may depend on user location, verification status, and applicable legal or regulatory requirements.
Additional platform details may be available after account creation, where applicable.
Identity, compliance, and other review steps may be required before access to certain materials or features.
Platform details, if applicable, should be reviewed in account materials before making any decision.
Any economic terms, if applicable, should be reviewed carefully in the relevant materials.

Private market interests may be illiquid, restricted, or difficult to transfer. Users should not assume that any secondary market will be available.
Valuations may reflect past financing rounds or other available information and may not represent a price at which any person can transact.
Company and sector risks may vary by business model, technology development, competition, regulation, and market conditions.
Operational, documentation, custody, or verification processes may involve limitations, delays, or dependencies.
Regulatory, tax, and legal requirements may change and may affect information availability, platform features, or user eligibility.


